Loading
institutionsInstitution
Rosalind and Morris Goodman Cancer Institute, McGill University
McGill's Goodman Cancer Institute builds on the 1965 discovery here of carcinoembryonic antigen, the first clinically used tumour marker; its groups study breast cancer metastasis, mRNA translation control and tumour metabolism, and William Muller's HER2 mouse models are used worldwide.
Also called: Goodman Cancer InstituteMcGill Cancer Centre
Overview
Founded in 1978 as the McGill Cancer Centre, the Goodman Cancer Institute builds on Phil Gold and Samuel Freedman's 1965 discovery at McGill of carcinoembryonic antigen (CEA), the first clinically used tumour marker and today the target of CEACAM5 antibody-drug conjugates. William Muller's MMTV-driven mouse models of HER2/Neu breast cancer are used worldwide; Morag Park and Peter Siegel study the breast tumour microenvironment and metastasis; Nahum Sonenberg's work on mRNA translation control (eIF4E) opened a therapeutic axis; and metabolism researchers including Julie St-Pierre link mitochondrial biology to tumour progression. The institute partners with McGill's teaching hospitals, the Jewish General Hospital's Segal Cancer Centre and the McGill University Health Centre, for translation.
Location
Montréal, QC, CA
Type
research institute · McGill University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#279 · 24 points (0 Newsweek + 0 NCI + 24 from 12 linked objects) · ranking
- Metastasis and tumour microenvironment
- Mouse models of breast cancer
- Translation control and metabolism
John Stagg
Director of the Rosalind and Morris Goodman Cancer Institute
Cancer immunotherapyImmuno-oncologyTherapeutic target discovery
Immunologist who studies why tumours resist immunotherapy and directs the Goodman Cancer Institute, McGill University's cancer research institute in Montreal.
Jonathan Spicer
Thoracic Surgeon and Associate Professor of Surgery, McGill University Health Centre
Thoracic surgeryNeoadjuvant immunotherapySurgical outcomes in trials
The surgeon on CheckMate 816 who showed neoadjuvant immunotherapy does not make lung cancer operations harder.
Similar pages
- TrialDual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
Shares CEACAM5, HER2, Colorectal cancer.
- TrialDual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
Shares CEACAM5, HER2, Colorectal cancer.
- IdeaBuild laboratory models of the organs cancer spreads to
Shares Patient-derived xenografts, Metastasis is understood least and studied last, Lab models that fail to predict what happens in patients.
- IdeaZebrafish avatars for a drug answer within a week
Shares Patient-derived xenografts, Lab models that fail to predict what happens in patients, Colorectal cancer.
- IdeaMake in vivo metastasis screens a required step in drug discovery
Shares Patient-derived xenografts, Metastasis is understood least and studied last, Lab models that fail to predict what happens in patients.
- IdeaGrow blood-borne tumour cells to test drugs on the cells that actually spread
Shares Patient-derived xenografts, Metastasis is understood least and studied last, Lab models that fail to predict what happens in patients.
- IdeaA ring-fenced metastasis programme with metastasis-specific endpoints
Shares Patient-derived xenografts, Metastasis is understood least and studied last, Melanoma, Colorectal cancer.
- IdeaBuild a human model of the barrier that guards the brain fluid
Shares Lab models that fail to predict what happens in patients, HER2-positive breast cancer, Melanoma.